List of Excipients in Branded Drug DOLO - NEUROBION ACETAMINOPHEN MAX

Generic Drugs Containing DOLO - NEUROBION ACETAMINOPHEN MAX

Company	Ingredient	NDC	Excipient
BENARD INDUSTRIES INC	acetaminophen	55959-179	CELLULOSE, MICROCRYSTALLINE
BENARD INDUSTRIES INC	acetaminophen	55959-179	HYDROXYETHYL CELLULOSE
BENARD INDUSTRIES INC	acetaminophen	55959-179	HYPROMELLOSE
BENARD INDUSTRIES INC	acetaminophen	55959-179	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in DOLO - NEUROBION ACETAMINOPHEN MAX?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYDROXYETHYL CELLULOSE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE

Dolo-Neurobion Acetaminophen Max: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 4, 2026

Dolo-Neurobion Acetaminophen Max is positioned as a branded oral analgesic combining acetaminophen with neurotropic B vitamins, typically thiamine, pyridoxine, and cyanocobalamin, depending on market and presentation. Its commercial value is driven primarily by brand recognition, dosing convenience, retail distribution, and the combination claim rather than by strong active-ingredient patent protection.

The strongest commercial opportunities are in differentiated immediate-release tablets, lower-sodium or sugar-free products, fast-dissolving presentations, stability-improved vitamin systems, and country-specific line extensions. The principal risks are regulatory classification, weak exclusivity for the active ingredients, substitution by plain acetaminophen, and uncertainty over whether the product is registered as a drug, OTC medicine, food supplement, or combination product in each country.

What is Dolo-Neurobion Acetaminophen Max?

Dolo-Neurobion Acetaminophen Max is a branded acetaminophen product associated with the Dolo-Neurobion franchise. Public product descriptions in Latin American markets generally associate the franchise with acetaminophen and neurotropic B vitamins, although strength, labeling, dosage form, and excipient composition can vary by jurisdiction.

Product element	Commercial role
Acetaminophen	Primary analgesic and antipyretic
Thiamine, vitamin B1	Supports the neurotropic positioning
Pyridoxine, vitamin B6	Supports nerve-related marketing claims
Cyanocobalamin, vitamin B12	Supports vitamin and neuropathy-related positioning
Oral solid dosage form	Enables low manufacturing cost and broad pharmacy distribution
"Max" designation	Signals a higher or premium strength, usually requiring careful dose communication

The product should not be treated as interchangeable with ordinary acetaminophen without reviewing the approved local label. The presence of B vitamins can affect permitted claims, warnings, target consumers, and regulatory classification.

What active ingredients are likely protected?

Acetaminophen has been used commercially for decades and is not protected by a commercially meaningful compound patent in major markets. Thiamine, pyridoxine, and cyanocobalamin are also established substances with extensive prior art.

The protection opportunity therefore lies in:

• The specific combination and dosage ratio
• A novel tablet or capsule formulation
• Improved dissolution or stability
• Taste masking
• Controlled or modified release
• A specific method of use, if accepted by the relevant regulator
• Packaging that protects moisture-sensitive vitamins
• A trademark and brand architecture

A simple combination of known ingredients generally has weaker patent prospects than a technically supported formulation. A patent application would need credible evidence of unexpected stability, bioavailability, manufacturing performance, tolerability, or clinical benefit.

What excipients are likely used in Dolo-Neurobion Acetaminophen Max?

The exact formula should be taken from the approved package insert, national regulatory dossier, or product-specific excipient declaration. A typical immediate-release tablet may use the following excipient architecture.

Excipient function	Common candidate materials	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Controls tablet weight and compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and supports brand identification
Color system	Iron oxides, titanium dioxide, approved lake colors	Provides product recognition
Moisture barrier	High-barrier blister, alu-alu blister, desiccant bottle	Protects vitamin potency and tablet integrity

Why vitamin stability affects excipient selection

Vitamin B12 and vitamin B6 can be sensitive to light, oxygen, moisture, and interactions with other formulation components. Cyanocobalamin stability can be affected by light exposure. Pyridoxine and thiamine also require control of processing and storage conditions.

A formulation strategy should therefore evaluate:

1. Moisture exposure during granulation and compression.
2. Compatibility between acetaminophen and each vitamin.
3. Light protection for cyanocobalamin.
4. Lubricant concentration and mixing time.
5. Coating weight and tablet dissolution.
6. Long-term potency of each active, not only acetaminophen.
7. Extractables and leachables from packaging.
8. Stability after opening for multidose bottles.

Wet granulation may improve content uniformity and compressibility but can increase exposure to water and heat. Direct compression reduces processing complexity but may create segregation risk when the active ingredients have different particle sizes and densities.

Which excipient strategy is commercially strongest?

For a mass-market product, a robust immediate-release tablet using microcrystalline cellulose, a modern superdisintegrant, low-level lubricant, and a protective film coat is usually the most practical platform. The formulation should prioritize:

• Dissolution within applicable pharmacopoeial limits
• Low tablet weight
• Strong resistance to chipping
• Stable vitamin potency
• Efficient high-speed compression
• Compatibility with blister packaging
• Low cost per dose

A lactose-free, gluten-free, sugar-free, and vegetarian formulation can expand retail and e-commerce positioning, but each claim requires local substantiation and label review.

What formulation patents could protect Dolo-Neurobion Acetaminophen Max?

The basic product concept is unlikely to support strong composition-of-matter exclusivity. Patent value would come from a narrow technical formulation claim.

Potential patentable formulation features

A defensible formulation program could investigate:

• A specific acetaminophen-to-B-vitamin ratio with improved stability
• Separate granulation of acetaminophen and the vitamin premix
• A moisture-protective coating around cyanocobalamin
• A bilayer tablet separating chemically incompatible components
• Taste-masked orally disintegrating tablets
• Rapid-release tablets with demonstrated pharmacokinetic or onset advantages
• A low-friability tablet produced by direct compression
• A modified-release product for sustained analgesic exposure
• A packaging-formulation combination that maintains vitamin potency
• A fixed-dose combination with reduced gastrointestinal burden

A patent claim directed only to "acetaminophen plus vitamins B1, B6, and B12" would face substantial novelty and obviousness risk. Stronger claims would connect the formulation architecture to measured results, such as improved impurity control, dissolution stability, or retained potency after accelerated storage.

How strong is the patent estate?

The likely patent estate is weak for the active ingredients and potentially moderate for a proprietary formulation, manufacturing process, or delivery system. Commercial exclusivity is more likely to depend on trademarks, regulatory data, distribution contracts, packaging, and consumer loyalty than on blocking patents.

Protection layer	Likely strength
Acetaminophen compound patent	Very low
B-vitamin compound patents	Very low
Basic fixed-dose combination	Low
Specific formulation process	Low to moderate
Stability-improved formulation	Moderate if supported by data
Trademark and trade dress	Moderate to strong
Manufacturing know-how	Moderate
Regulatory exclusivity	Jurisdiction-dependent
Distribution and retail access	Potentially strong

What is the FDA and Orange Book status?

Dolo-Neurobion Acetaminophen Max is not automatically an FDA-approved U.S. product merely because the brand is marketed in another country. FDA status must be assessed by product, sponsor, dosage form, strength, and application number.

A U.S. product containing acetaminophen may be regulated under the FDA OTC monograph framework or through an approved drug application, depending on its ingredients, claims, and formulation. Combination products containing acetaminophen and vitamins require a separate assessment of whether the vitamin ingredients and the proposed therapeutic claims fit the applicable regulatory pathway.

The Orange Book lists approved drug products and patent information associated with approved applications. A foreign-market Dolo-Neurobion product may have no Orange Book listing in the United States. If a U.S. version is marketed under an approved application, any listed patents would need to be verified in the FDA Orange Book and applicable patent-listing records.[1]

What FDA issues matter commercially?

The main U.S. regulatory issues are:

• Acetaminophen dose per unit and maximum daily exposure
• Liver injury warnings
• Duplicate acetaminophen exposure from other products
• Permitted claims for B vitamins
• Label prominence and readability
• Manufacturing under current good manufacturing practices
• Drug facts requirements
• Stability and dissolution
• Pediatric and pregnancy labeling
• Whether "Max" creates confusion about safe daily use

FDA has repeatedly emphasized the risk of unintentional acetaminophen overdose from multiple products. A higher-strength "Max" presentation must use clear unit-dose instructions and prominent warnings.[2]

When does Dolo-Neurobion Acetaminophen Max lose exclusivity?

There is no single global exclusivity date. Exclusivity depends on the country, marketing authorization, trademark registrations, patent filings, regulatory pathway, and any approved formulation changes.

For the active ingredients, practical generic availability already exists in most major markets. A competitor may be able to launch a product containing the same actives if it satisfies local registration requirements and avoids enforceable formulation, trademark, or method-of-use rights.

Exclusivity mechanism	Typical commercial duration
Acetaminophen substance exclusivity	Generally expired
B-vitamin substance exclusivity	Generally expired
Trademark registration	Renewable in most jurisdictions
Formulation patent	Usually up to 20 years from earliest nonprovisional filing, subject to local law
Regulatory data exclusivity	Country-specific
OTC monograph position	No conventional patent-like monopoly
Trade secret manufacturing process	Potentially indefinite if protected
Distribution agreement	Contract-specific

Patent expiration cannot be stated accurately without verified patent-family records for the relevant country and product owner. A product-level exclusivity review should separate the brand, formulation, manufacturing process, and regulatory dossier.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is relevant only if a U.S. product is approved under an NDA or ANDA framework with listed patents in the Orange Book. It is not automatically relevant to a foreign-market product or to a product marketed under an OTC monograph pathway.

If a U.S. NDA contains listed formulation or method-of-use patents, an ANDA applicant could challenge those patents through a Paragraph IV certification. The likely challenge points would include:

• Obviousness of the fixed-dose combination
• Lack of novelty in tablet composition
• Written-description support for stability claims
• Enablement of broad excipient claims
• Noninfringement of coating or granulation limitations
• Invalidity of method-of-use claims based on known analgesic or vitamin uses

Because acetaminophen and B vitamins are old ingredients, any litigation value would concentrate on narrow formulation patents. Broad combination claims would face greater invalidity exposure.

What generic entry risks exist?

Generic and private-label entry risk is high where the product is sold primarily as an oral tablet with conventional excipients and no active patent barrier.

Likely competitor categories

1. Plain acetaminophen products priced below the branded combination.
2. Generic acetaminophen plus B-vitamin combinations.
3. Diclofenac or ibuprofen products marketed for pain.
4. B-vitamin products marketed for neuropathic symptoms.
5. Rapid-release and effervescent acetaminophen products.
6. Retailer-owned private-label analgesics.
7. Regional brands using similar neurotropic positioning.

A generic entrant does not need to duplicate the proprietary excipient system if the dosage form, release profile, quality, and labeling remain compliant. This limits the defensive value of ordinary excipient selection.

What commercial opportunities exist for excipient innovation?

1. Fast-dissolving and orally disintegrating formats

A rapidly disintegrating tablet could create a premium niche for consumers seeking faster administration without water. Crospovidone, croscarmellose sodium, mannitol, and low-moisture processing are possible platform components.

The product would need strong taste-masking because acetaminophen and B vitamins can create an unpleasant sensory profile. Flavoring and sweetener systems must be compatible with stability and local excipient rules.

2. Effervescent and soluble products

Effervescent formats can differentiate the brand and support perceived rapid action. They also create technical challenges:

• Moisture sensitivity
• Packaging cost
• Carbon dioxide-generating acid-base systems
• Sodium content
• Vitamin stability
• Dose uniformity

A low-sodium or sodium-free approach could improve suitability for consumers monitoring sodium intake.

3. Sugar-free and diabetic-positioned products

A sugar-free tablet or sachet can broaden use occasions. Polyols, high-intensity sweeteners, or neutral film-coated tablets may support this strategy. Excessive polyol content can create gastrointestinal tolerability problems, and all claims require local regulatory review.

4. Vegetarian and allergen-conscious products

Plant-derived or synthetic alternatives to animal-derived excipients can support pharmacy and e-commerce channels. Capsule shell composition, magnesium stearate source, lactose, gluten, and colorants should be assessed for certification and label claims.

5. Stability-protected vitamin premix

A differentiated premix that reduces vitamin degradation could be more valuable than a new tablet excipient. Commercial advantages include longer shelf life, fewer out-of-specification batches, and less restrictive storage conditions.

6. Premium packaging

Aluminum-aluminum blisters or high-barrier cold-form foil may protect the vitamin combination better than standard PVC blister packs. Packaging can become a cost-effective substitute for more complex formulation technology, provided stability data demonstrate the benefit.

How does Dolo-Neurobion compare with plain acetaminophen?

Criterion	Dolo-Neurobion Acetaminophen Max	Plain acetaminophen
Core consumer proposition	Analgesia plus neurotropic vitamin positioning	Analgesia and fever reduction
Ingredient complexity	Higher	Lower
Manufacturing cost	Higher	Lower
Patent barrier	Generally weak	Very weak
Labeling complexity	Higher	Lower
Differentiation	Brand and combination	Price and availability
Generic substitution risk	High	Very high
Premium pricing potential	Moderate	Limited
Stability burden	Higher due to vitamins	Lower
Retail education requirement	Higher	Lower

The combination can command a premium only if consumers, pharmacists, or clinicians perceive added value. Marketing claims implying treatment of neuropathic pain require particular scrutiny because vitamin presence alone does not establish clinical efficacy for every pain condition.

Which licensing and partnership opportunities are available?

Potential deal structures include:

• Local licensing of the Dolo-Neurobion trademark
• Contract manufacturing of the tablet or vitamin premix
• Regional distribution agreements
• Co-development of an orally disintegrating or effervescent version
• Packaging technology licensing
• Private-label supply for pharmacy chains
• Manufacturing transfer with quality and stability know-how
• Co-promotion with pain, neurology, or primary-care portfolios

The most valuable licensable asset is likely the brand and market authorization package rather than a broad active-ingredient patent. A transaction should distinguish ownership of trademarks, regulatory dossiers, manufacturing methods, product artwork, stability data, and local registrations.

What litigation and settlement risks should companies monitor?

Relevant disputes may involve:

• Trademark infringement involving "Dolo" or "Neurobion"
• Trade dress copying
• Regulatory approval of a similar combination
• Misleading therapeutic claims
• Patent claims covering a particular formulation
• Manufacturing confidentiality and employee mobility
• Distribution termination or territory restrictions
• Advertising complaints concerning vitamin-related analgesic benefits

Settlement agreements could include geographic carve-outs, delayed entry, trademark coexistence, restricted claims, or supply arrangements. No settlement date or litigation outcome should be assumed without a verified docket and jurisdiction-specific record.

Key Takeaways

• Dolo-Neurobion Acetaminophen Max is commercially differentiated mainly by branding, combination positioning, and distribution.
• Acetaminophen and B vitamins have little practical compound-patent value.
• The strongest IP opportunity is a technically supported formulation, stability system, delivery format, or manufacturing process.
• Moisture, light, and compatibility control are central excipient issues because of the vitamin components.
• Generic entry risk is high for a conventional immediate-release tablet.
• Fast-dissolving, effervescent, sugar-free, low-sodium, and stability-protected products offer the clearest line-extension opportunities.
• U.S. Orange Book and Paragraph IV analysis applies only if a corresponding U.S. approved application and listed patents exist.
• Trademarks, regulatory registrations, packaging, manufacturing know-how, and channel access may provide more durable commercial protection than patents.

FAQs

Does Dolo-Neurobion Acetaminophen Max have a strong patent barrier?

Probably not at the active-ingredient level. Any meaningful patent protection would need to arise from a specific formulation, manufacturing process, stability result, delivery system, or approved method of use.

Can a generic company copy the excipients?

Usually yes, if the generic product meets applicable quality, dissolution, stability, labeling, and regulatory requirements and does not infringe enforceable formulation or process claims. It does not generally need to use the same excipient suppliers.

Is Dolo-Neurobion Acetaminophen Max an OTC medicine?

Its classification depends on the country, approved claims, strength, and registration pathway. The same brand family may have different regulatory status in different markets.

Which packaging is best for the B-vitamin combination?

High-barrier blister packaging, particularly aluminum-aluminum blister, can provide stronger protection against moisture and light than standard blister materials. The final choice should follow comparative stability data and cost analysis.

Can a new Dolo-Neurobion formulation obtain regulatory exclusivity?

Potentially, depending on the jurisdiction and approval pathway. Regulatory exclusivity would attach to the qualifying new product or data package, not automatically to the established acetaminophen and vitamin ingredients.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2023). Acetaminophen and liver injury: Q&A for consumers. https://www.fda.gov/drugs/information-drug-class/acetaminophen-and-liver-injury

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/page/quality-guidelines

5. United States Pharmacopeia. (2024). USP-NF general chapters and monographs. https://www.usp.org/compounding/general-chapters

6. World Health Organization. (2022). WHO guideline on stability evaluation of active pharmaceutical ingredients and finished pharmaceutical products. World Health Organization.